High Expression of PDLIM2 Predicts a Poor Prognosis in Prostate Cancer and Is Correlated with Epithelial-Mesenchymal Transition and Immune Cell Infiltration
Table 1
Association between low- or high-PDLIM2 mRNA expression and clinicopathological features in TCGA-PRAD cohort.
Characteristic
Low expression of PDLIM2
High expression of PDLIM2
249
250
Age, (%)
0.054a
≤60
123 (24.6%)
101 (20.2%)
>60
126 (25.3%)
149 (29.9%)
T stage, (%)
0.150a
T2
105 (21.3%)
84 (17.1%)
T3
136 (27.6%)
156 (31.7%)
T4
5 (1%)
6 (1.2%)
N stage, (%)
0.057a
N0
180 (42.3%)
167 (39.2%)
N1
31 (7.3%)
48 (11.3%)
M stage, (%)
1.000b
M0
226 (49.3%)
229 (50%)
M1
1 (0.2%)
2 (0.4%)
Primary therapy outcome, (%)
<0.001a
PD
14 (3.2%)
14 (3.2%)
SD
10 (2.3%)
19 (4.3%)
PR
9 (2.1%)
31 (7.1%)
CR
183 (41.8%)
158 (36.1%)
Race, (%)
0.215a
Asian
9 (1.9%)
3 (0.6%)
Black or African American
28 (5.8%)
29 (6%)
White
205 (42.4%)
210 (43.4%)
Residual tumor, (%)
0.051b
R0
169 (36.1%)
146 (31.2%)
R1
62 (13.2%)
86 (18.4%)
R2
3 (0.6%)
2 (0.4%)
Zone of origin, (%)
0.196b
Central zone
3 (1.1%)
1 (0.4%)
Overlapping/multiple zones
53 (19.3%)
73 (26.5%)
Peripheral zone
62 (22.5%)
75 (27.3%)
Transition zone
6 (2.2%)
2 (0.7%)
PSA (ng/ml), (%)
0.801a
<4
212 (48%)
203 (45.9%)
≥4
15 (3.4%)
12 (2.7%)
Gleason score, (%)
0.003a
6
28 (5.6%)
18 (3.6%)
7
138 (27.7%)
109 (21.8%)
8
31 (6.2%)
33 (6.6%)
9
51 (10.2%)
87 (17.4%)
10
1 (0.2%)
3 (0.6%)
Abbreviations: CR: complete response; PD: progressive disease; SD: stable disease; PR: partial response; R0: no residual tumor; R1: microscopic residual tumor; R2: macroscopic residual tumor; PSA: prostate-specific antigen. All results are presented as (%); achi-square test; bFisher test.
